EGFR and metastatic neoplasm: Firstly, despite our focus on patients with oligo-residual NSCLC and EGFR/ALK wildtype, there remains inherent heterogeneity, such as driver gene alteration status, histology, overall disease burden, metastatic disease interval, and previous systemic therapy.